Takeda Pharmaceutical plans to implement the issuance of 16,989,076 new shares and share buyback on July 8, 2026, raising approximately 8.58 billion yen. This is part of a long-term incentive system for overseas employees, with beneficiaries including 10,557 employees of the Company and its subsidiaries.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4502-20260609-01.pdf","jir_short_summary":"Takeda Pharmaceutical plans to implement the issuance of 16,989,076 new shares and share buyback on July 8, 2026, raising approximately 8.58 billion yen. This is part of a long-term incentive system for overseas employees, with beneficiaries including 10,557 employees of the Company and its subsidiaries.","jir_summary":"### Overview of Capital Policy\nTakeda Pharmaceutical will carry out the issuance of new shares and share buyback on July 8, 2026, as part of the long-term incentive system for overseas employees. A total of 16,989,076 shares will be allocated to beneficiaries, including the type of shares, with a total value of approximately 8.58 billion yen. This aims to incentivize employee retention and strategic advancement. The newly issued shares will be allocated to employees of the Company and its subsidiaries, and the share buyback will be conducted through the disposal of treasury stock. The issuance and disposal prices are determined based on the closing prices of the Tokyo Stock Exchange on the business day prior to the decision date.\n\n### Purpose and Future Outlook\nThis share buyback is part of a long-term incentive scheme aimed at employee retention and enhancement of corporate value. The beneficiaries include 10,557 employees of the Company and its subsidiaries, who will receive not only allocated shares but also cash reward claims. Aside from strengthening financial strategy through fundraising, the company plans to continue prioritizing employee motivation and maximizing corporate value.","jir_financial_highlights":"Number of Newly Issued Shares: 10,892,917 shares (Unknown)\nNumber of Shares Disposed through Share Buyback: 6,096,159 shares (Unknown)\nTotal Amount: 85,794,833,800 yen (Unknown)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #IRRelated, #JapanStocks","jir_key_figures":"Number of newly issued shares: 10,892,917 shares\nNumber of shares disposed through share buyback: 6,096,159 shares\nTotal amount: 85,794,833,800 yen","jir_meta_title":"\u3010Takeda Pharmaceutical\u3011Long-term Incentive System Introduction and Share Buyback\uff5cJune 2026","jir_meta_description":"Takeda Pharmaceutical plans to issue new shares and conduct share buyback in July 2026, raising approximately 8.58 billion yen as part of a long-term incentive system for employees.","jir_og_title":"\u3010Takeda Pharmaceutical\u3011Long-term Incentive System and Share Buyback\uff5cJune 2026","jir_og_description":"Takeda Pharmaceutical will issue new shares and carry out share buyback in July 2026 to enhance employee retention and corporate value.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-62584","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n